Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment
Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and approximately one-fifth of them are diagnosed in males. The clinical presentation of PRLomas results from direct prolactin (PRL) action, duration and severity of hyperprolactinemia, and tumor mass effect. Male PRLoma...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1338345/full |
| _version_ | 1797333755126349824 |
|---|---|
| author | Lukasz Dzialach Joanna Sobolewska Zuzanna Zak Wioleta Respondek Przemysław Witek |
| author_facet | Lukasz Dzialach Joanna Sobolewska Zuzanna Zak Wioleta Respondek Przemysław Witek |
| author_sort | Lukasz Dzialach |
| collection | DOAJ |
| description | Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and approximately one-fifth of them are diagnosed in males. The clinical presentation of PRLomas results from direct prolactin (PRL) action, duration and severity of hyperprolactinemia, and tumor mass effect. Male PRLomas, compared to females, tend to be larger and more invasive, are associated with higher PRL concentration at diagnosis, present higher proliferative potential, are more frequently resistant to standard pharmacotherapy, and thus may require multimodal approach, including surgical resection, radiotherapy, and alternative medical agents. Therefore, the management of PRLomas in men is challenging in many cases. Additionally, hyperprolactinemia is associated with a significant negative impact on men’s health, including sexual function and fertility potential, bone health, cardiovascular and metabolic complications, leading to decreased quality of life. In this review, we highlight the differences in pathogenesis, clinical presentation and treatment of PRLomas concerning the male sex. |
| first_indexed | 2024-03-08T08:09:35Z |
| format | Article |
| id | doaj.art-881123ca516c4d9f9b50c6bb29e083c9 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-08T08:09:35Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-881123ca516c4d9f9b50c6bb29e083c92024-02-02T09:42:25ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-02-011510.3389/fendo.2024.13383451338345Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatmentLukasz Dzialach0Joanna Sobolewska1Zuzanna Zak2Wioleta Respondek3Przemysław Witek4Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, PolandDepartment of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, PolandDepartment of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, PolandDepartment of Internal Medicine, Endocrinology and Diabetes, Mazovian Brodnowski Hospital, Warsaw, PolandDepartment of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, PolandProlactinomas (PRLomas) constitute approximately half of all pituitary adenomas and approximately one-fifth of them are diagnosed in males. The clinical presentation of PRLomas results from direct prolactin (PRL) action, duration and severity of hyperprolactinemia, and tumor mass effect. Male PRLomas, compared to females, tend to be larger and more invasive, are associated with higher PRL concentration at diagnosis, present higher proliferative potential, are more frequently resistant to standard pharmacotherapy, and thus may require multimodal approach, including surgical resection, radiotherapy, and alternative medical agents. Therefore, the management of PRLomas in men is challenging in many cases. Additionally, hyperprolactinemia is associated with a significant negative impact on men’s health, including sexual function and fertility potential, bone health, cardiovascular and metabolic complications, leading to decreased quality of life. In this review, we highlight the differences in pathogenesis, clinical presentation and treatment of PRLomas concerning the male sex.https://www.frontiersin.org/articles/10.3389/fendo.2024.1338345/fulldopamine agonistsmen’s healthpituitary adenomapituitary neuroendocrine tumorprolactin |
| spellingShingle | Lukasz Dzialach Joanna Sobolewska Zuzanna Zak Wioleta Respondek Przemysław Witek Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment Frontiers in Endocrinology dopamine agonists men’s health pituitary adenoma pituitary neuroendocrine tumor prolactin |
| title | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment |
| title_full | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment |
| title_fullStr | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment |
| title_full_unstemmed | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment |
| title_short | Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment |
| title_sort | prolactin secreting pituitary adenomas male specific differences in pathogenesis clinical presentation and treatment |
| topic | dopamine agonists men’s health pituitary adenoma pituitary neuroendocrine tumor prolactin |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1338345/full |
| work_keys_str_mv | AT lukaszdzialach prolactinsecretingpituitaryadenomasmalespecificdifferencesinpathogenesisclinicalpresentationandtreatment AT joannasobolewska prolactinsecretingpituitaryadenomasmalespecificdifferencesinpathogenesisclinicalpresentationandtreatment AT zuzannazak prolactinsecretingpituitaryadenomasmalespecificdifferencesinpathogenesisclinicalpresentationandtreatment AT wioletarespondek prolactinsecretingpituitaryadenomasmalespecificdifferencesinpathogenesisclinicalpresentationandtreatment AT przemysławwitek prolactinsecretingpituitaryadenomasmalespecificdifferencesinpathogenesisclinicalpresentationandtreatment |